GR3030383T3 - Solution containing igf-1. - Google Patents

Solution containing igf-1.

Info

Publication number
GR3030383T3
GR3030383T3 GR990401477T GR990401477T GR3030383T3 GR 3030383 T3 GR3030383 T3 GR 3030383T3 GR 990401477 T GR990401477 T GR 990401477T GR 990401477 T GR990401477 T GR 990401477T GR 3030383 T3 GR3030383 T3 GR 3030383T3
Authority
GR
Greece
Prior art keywords
igf
pct
mmol
formulation
relates
Prior art date
Application number
GR990401477T
Other languages
English (en)
Inventor
Ebba Florin-Robertsson
Jonas Fransson
Diane Moore
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of GR3030383T3 publication Critical patent/GR3030383T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GR990401477T 1993-01-15 1999-06-01 Solution containing igf-1. GR3030383T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9300105A SE9300105D0 (sv) 1993-01-15 1993-01-15 Stable protein solution
PCT/SE1994/000010 WO1994015584A1 (en) 1993-01-15 1994-01-10 Solution containing igf-1

Publications (1)

Publication Number Publication Date
GR3030383T3 true GR3030383T3 (en) 1999-09-30

Family

ID=20388550

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401477T GR3030383T3 (en) 1993-01-15 1999-06-01 Solution containing igf-1.

Country Status (12)

Country Link
US (1) US5783559A (el)
EP (1) EP0679079B1 (el)
JP (1) JP3580816B2 (el)
AT (1) ATE177942T1 (el)
AU (1) AU676882B2 (el)
DE (1) DE69417397T2 (el)
DK (1) DK0679079T3 (el)
ES (1) ES2131673T3 (el)
GR (1) GR3030383T3 (el)
NZ (1) NZ259951A (el)
SE (1) SE9300105D0 (el)
WO (1) WO1994015584A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AU4424497A (en) * 1996-09-13 1998-04-02 Transkaryotic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
DE69814133T2 (de) * 1997-11-07 2004-04-01 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung um die löslichkeit von igf-i zu erhöhen
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
UY25790A1 (es) * 1998-11-06 2000-08-21 Bio Sidus S A Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
IL145597A0 (en) 1999-04-08 2002-06-30 Genentech Inc Composition based on oppositely-charged polypeptides
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
KR20050012224A (ko) 2002-05-21 2005-01-31 다이이찌 산토리 파마 가부시키가이샤 그렐린 함유 의약 조성물
US20080193997A1 (en) * 2004-08-24 2008-08-14 Kenji Kangawa Liquid Preparation of Physiologically Active Peptide
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Jcrファーマ株式会社 蛋白質含有水性液剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke

Also Published As

Publication number Publication date
ES2131673T3 (es) 1999-08-01
AU676882B2 (en) 1997-03-27
SE9300105D0 (sv) 1993-01-15
DE69417397T2 (de) 1999-09-09
EP0679079B1 (en) 1999-03-24
DK0679079T3 (da) 1999-10-11
JPH08505617A (ja) 1996-06-18
US5783559A (en) 1998-07-21
NZ259951A (en) 1996-10-28
DE69417397D1 (de) 1999-04-29
EP0679079A1 (en) 1995-11-02
AU5893994A (en) 1994-08-15
ATE177942T1 (de) 1999-04-15
JP3580816B2 (ja) 2004-10-27
WO1994015584A1 (en) 1994-07-21

Similar Documents

Publication Publication Date Title
GR3030383T3 (en) Solution containing igf-1.
EP1201241B8 (en) Compositions containing capsaicin or capsaicin analogues and an anesthetic
HK1107103A1 (en) Purification and stabilization of peptide and proteins in pharmaceutical agents
SG48704A1 (en) Improved amino acid solutions for treatment of peritoneal dialysis patients
MY109309A (en) Improvements in or relating to somatostatins
SG50567A1 (en) Pharmaceutical preparations containing plasminogen activators
Nanninga et al. Role of magnesium and calcium in the first and second contraction of glycerin-extracted muscle fibers
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
PL320342A1 (en) Thrombin inhibitor containing infusion solution, stable during storage
GR3034096T3 (en) A method for treatment of patients with chronic liver disease.
CA2153787A1 (en) Solution containing igf-1
ATE198549T1 (de) Verwendung von dehydroepiandrosteron zur suchtbehandlung
CA2165271A1 (en) Reduction of adipose tissue
JP2001187750A (ja) 感染部位検知方法、それに使用する組成物およびその組成物の製造方法
UA43413C2 (uk) Спосіб одержання ін'єкційного засобу "ерихрозид" для лікування серцево-судинних захворювань
BG94567A (en) Medicaments for the treatment of aids and method for its application
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
UA27060C2 (uk) Спосіб стимулюваhhя зовhішhьої секреції підшлуhкової залози
UA7952A (uk) Препарат для лікування гіпогалактії та спосіб лікування гіпогалактії
UA28810A (uk) Спосіб обробки нагнітальної свердловини
SU1823177A1 (ru) Способ подготовки сосудистых ксенопротезов и клапанов сердца к имплантации